BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BioMarin Pharmaceutical is viewed favorably because its core VOXZOGO franchise remains financially meaningful, generating $253M in 2Q26 and growing 15% quarter over quarter, while the company now monetizes a key competitor through 18% to 20% royalties on YUVIWEL net sales through May 2030. The settlement also removes major patent and ITC litigation overhangs, adding modeled royalty revenue of $10M, $40M, $66M, $90M, and $47M across FY26E-FY30E and lifting non-GAAP EPS estimates to $5.01, $6.78, $7.50, $8.51, and $9.24. Fundamentally, the agreement preserves BioMarin’s IP, validates the commercial importance of convenience in achondroplasia, and buys time for pipeline assets such as BMN 333 and broader business development to drive the post-VOXZOGO growth path.

BioMarin Pharmaceutical is facing a cautious fundamental backdrop because its valuation already embeds significant assumptions, with a DCF-based EV of about $14.0B dependent on a 10% discount rate and 1% terminal growth rate. Its balance sheet also looks constrained, with roughly $3.5B of debt outstanding by end-3Q27 against estimated cash and equivalents of about $1.9B, leaving limited flexibility if growth underperforms. The negative outlook is reinforced by concrete execution and competitive risks, including faster-than-expected VOXZOGO share loss to YUVIWEL and other ACH competitors, weaker uptake in HCH, and BMN 333 failing to establish sufficient differentiation to strengthen the franchise.